DevaCell is rapidly advancing a pipeline of therapeutic product candidates based on a proprietary synthetic vector engineering platform technology. Key therapeutic segments include - oncolytic cancer immunotherapy, gene therapy/gene editing and vaccines. Based on the transformative and proprietary ONCoat, nanoparticle-based synthetic vector platform technology, the company's lead therapeutic program is a synthetic vector based oncolytic cancer immunotherapy with multiple transgene payloads encoded into an engineered, adenovirus (Ad5) backbone, targeting solid tumors. The program is currently transitioning to IND-enabling studies, with human clinical trials anticipated to launch by year-end 2021. In the infectious disease segment, advancing to IND-enabling studies is an COVID-19 vaccine based on the same Ad5 backbone, engineered to express the SARSCoV19 virus spike protein. The company's gene therapy/gene editing program is currently in discovery research with product candidates anticipated to advance to IND-enabling studies in the second half of 2021.